Skip to Content

Supernus Pharmaceuticals, Inc.

Company NameSupernus Pharmaceuticals, Inc.
Stock SymbolSUPN

On April 8, 2024, Supernus announced that the FDA had issued a Complete Response Letter (“CRL”) in response to the Company’s New Drug Application for its Parkinson’s disease treatment, SPN-830. The CRL stated that “the review cycle for the application is complete, but that the application is not ready for approval in its present form." Specifically, “two areas that require additional review by the FDA or additional information to be provided to the FDA," respectively relating to product quality and the master file for the infusion device.

On this news, Supernus’s stock price fell $2.12, or 6.3%, to close at $31.43 per share on April 8, 2024, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Supernus Pharmaceuticals, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd